Impact of treatments for osteoporosis on cartilage biomarkers in humans

Osteoporosis International

Volumn 23, Issue 8 SUPPL, 2012, Pages

  Richette, P ^a   Roux, C ^b  

^a HÔPITAL LARIBOISIÈRE   (France)

^b Université Paris Descartes ^*  (France)

Author keywords

Biomarkers; Bisphosphonate; Bone; Calcitonin; Estrogens; Osteoarthritis; Selective estrogen receptor modulators; Strontium ranelate

Indexed keywords

ALENDRONIC ACID; BIOLOGICAL MARKER; CALCITONIN; CARBOXY TERMINAL TELOPEPTIDE; COLLAGEN TYPE 2; ESTROGEN DERIVATIVE; MATRIX METALLOPROTEINASE; PLACEBO; RISEDRONIC ACID; SALCATONIN; SELECTIVE ESTROGEN RECEPTOR MODULATOR; STRONTIUM RANELATE; TIBOLONE; TILUDRONIC ACID; ZOLEDRONIC ACID; BONE DENSITY CONSERVATION AGENT; COLLAGEN II C TELOPEPTIDE; COLLAGEN II C-TELOPEPTIDE; PEPTIDE FRAGMENT;

ARTICLE; CARTILAGE; CARTILAGE DEGENERATION; DRUG DOSE REDUCTION; ENZYME ACTIVITY; GOLD STANDARD; HOMEOSTASIS; HUMAN; JOINT CAVITY; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; PRIORITY JOURNAL; RADIOGRAPHY; ARTICULAR CARTILAGE; DRUG EFFECT; METABOLISM; OSTEOARTHRITIS; REVIEW; URINE;

BIOLOGICAL MARKERS; BONE DENSITY CONSERVATION AGENTS; CARTILAGE, ARTICULAR; COLLAGEN TYPE II; HUMANS; OSTEOARTHRITIS; OSTEOPOROSIS; PEPTIDE FRAGMENTS;

EID: 84878246667     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-012-2165-9     Document Type: Article

References (27)

1. Funck-Brentano T, Cohen-Solal M (2011) Crosstalk between cartilage and bone: when bone cytokines matter. Cytokine Growth Factor Rev 22(2):91-97
2. Kwan Tat S, Lajeunesse D, Pelletier JP, Martel-Pelletier J (2010) Targeting subchondral bone for treating osteoarthritis: what is the evidence? Best Pract Res Clin Rheumatol 24(1):51-70
3. Kadri A, Funck-Brentano T, Lin H et al (2010) Inhibition of bone resorption blunts osteoarthritis in mice with high bone remodelling. Ann Rheum Dis 69(8):1533-1538
4. Kadri A, Ea HK, Bazille C, Hannouche D, Liote F, Cohen-Solal ME (2008) Osteoprotegerin inhibits cartilage degradation through an effect on trabecular bone in murine experimental osteoarthritis. Arthritis Rheum 58(8):2379-2386
5. Kraus VB, Burnett B, Coindreau J et al (2011) Application of biomarkers in the development of drugs intended for the treatment of osteoarthritis. Osteoarthritis Cartilage 19(5):515-542
6. Richette P, Corvol M, Bardin T (2003) Estrogens, cartilage, and osteoarthritis. Joint Bone Spine 70(4):257-262
7. Sniekers YH, Weinans H, van Osch GJ, van Leeuwen JP (2010) Oestrogen is important for maintenance of cartilage and subchondral bone in a murine model of knee osteoarthritis. Arthritis Res Ther 12(5):R182
8. Sniekers YH, Weinans H, Bierma-Zeinstra SM, van Leeuwen JP, van Osch GJ (2008) Animal models for osteoarthritis: the effect of ovariectomy and estrogen treatment - a systematic approach. Osteoarthritis Cartilage 16(5):533-541
9. Richette P, Dumontier MF, Francois M et al (2004) Dual effects of 17beta-oestradiol on interleukin 1beta-induced proteoglycan degradation in chondrocytes. Ann Rheum Dis 63(2):191-199
10. Richette P, Dumontier MF, Tahiri K et al (2007) Oestrogens inhibit interleukin 1beta-mediated nitric oxide synthase expression in articular chondrocytes through nuclear factor-kappa B impairment. Ann Rheum Dis 66(3):345-350
11. Bay-Jensen AC, Tabassi NC, Sondergaard LV et al (2009) The response to oestrogen deprivation of the cartilage collagen degradation marker, CTX-II, is unique compared with other markers of collagen turnover. Arthritis Res Ther 11(1):R9
12. Mouritzen U, Christgau S, Lehmann HJ, Tanko LB, Christiansen C (2003) Cartilage turnover assessed with a newly developed assay measuring collagen type II degradation products: influence of age, sex, menopause, hormone replacement therapy, and body mass index. Ann Rheum Dis 62(4):332-336
13. Ravn P, Warming L, Christgau S, Christiansen C (2004) The effect on cartilage of different forms of application of postmenopausal estrogen therapy: comparison of oral and transdermal therapy. Bone 35(5):1216-1221
14. Christgau S, Tanko LB, Cloos PA et al (2004) Suppression of elevated cartilage turnover in postmenopausal women and in ovariectomized rats by estrogen and a selective estrogen-receptor modulator (SERM). Menopause 11(5):508-518
15. Karsdal MA, Byrjalsen I, Leeming DJ, Christiansen C (2008) Tibolone inhibits bone resorption without secondary positive effects on cartilage degradation. BMC Musculoskelet Disord 9:153
16. Sondergaard BC, Madsen SH, Segovia-Silvestre T et al (2010) Investigation of the direct effects of salmon calcitonin on human osteoarthritic chondrocytes. BMC Musculoskelet Disord 11:62
17. Karsdal MA, Sondergaard BC, Arnold M, Christiansen C (2007) Calcitonin affects both bone and cartilage: a dual action treatment for osteoarthritis? Ann N Y Acad Sci 1117:181-195
18. Manicourt DH, Azria M, Mindeholm L, Thonar EJ, Devogelaer JP (2006) Oral salmon calcitonin reduces Lequesne's algofunctional index scores and decreases urinary and serum levels of biomarkers of joint metabolism in knee osteoarthritis. Arthritis Rheum 54(10):3205-3211
19. Karsdal MA, Byrjalsen I, Henriksen K et al (2010) The effect of oral salmon calcitonin delivered with 5-CNAC on bone and cartilage degradation in osteoarthritic patients: a 14-day randomized study. Osteoarthritis Cartilage 18(2):150-159
20. Bagger YZ, Tanko LB, Alexandersen P et al (2005) Oral salmon calcitonin induced suppression of urinary collagen type II degradation in postmenopausal women: a new potential treatment of osteoarthritis. Bone 37(3):425-430
21. Alexandersen P, Karsdal MA, Qvist P, Reginster JY, Christiansen C (2007) Strontium ranelate reduces the urinary level of cartilage degradation biomarker CTX-II in postmenopausal women. Bone 40(1):218-222
22. Alexandersen P, Karsdal MA, Byrjalsen I, Christiansen C (2011) Strontium ranelate effect in postmenopausal women with different clinical levels of osteoarthritis. Climacteric 14(2):236-243
23. Henrotin Y, Labasse A, Zheng SX et al (2001) Strontium ranelate increases cartilage matrix formation. J Bone Miner Res 16(2):299-308
24. Saag KG (2008) Bisphosphonates for osteoarthritis prevention: "Holy Grail" or not? Ann Rheum Dis 67(10):1358-1359
25. Moreau M, Rialland P, Pelletier JP et al (2011) Tiludronate treatment improves structural changes and symptoms of osteoarthritis in the canine anterior cruciate ligament model. Arthritis Res Ther 13(3):R98
26. Bingham CO 3rd, Buckland-Wright JC, Garnero P et al (2006) Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: results of the two-year multinational knee osteoarthritis structural arthritis study. Arthritis Rheum 54(11):3494-3507
27. Spector TD, Conaghan PG, Buckland-Wright JC et al (2005) Effect of risedronate on joint structure and symptoms of knee osteoarthritis: results of the BRISK randomized, controlled trial [ISRCTN01928173]. Arthritis Res Ther 7(3):R625-R633